Skip to content

Lena K L Oestreich

6 papers in the library · 10 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Psychedelics in Mental Health: Opportunities and Challenges.

Brain and Behavior July 1, 2026 Lena K L Oestreich, Nathalie M. Rieser

Psychedelic and substance-assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding...

A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies.

European Journal of Psychotraumatology March 19, 2026 Philip Gerrans, Hugh McGovern, Jakob Hohwy et al.

Background: Complex post-traumatic stress disorder (C-PTSD) is a trauma-related condition characterized by pervasive disturbances in affect regulation, self-concept, and interpersonal functioning that extend beyond the symptom profile of post-traumatic stress disorder (PTSD). While neurobiological studies have implicated limbic, salience, and prefrontal systems in C-PTSD, mechanistic accounts...

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers

Australian & New Zealand Journal of Psychiatry July 15, 2025 Zohaib Nadeem, Stephen Parker, Hugh McGovern et al. 7 citations

Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers’ attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. Methods: A cross-sectional survey was...

Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology

May 26, 2024 Hugh McGovern, Nick Wellman, Brendan Hutchinson et al. 2 citations preprint

Psychedelics (hallucinogenic 5-HT2A agonists such as psilocybin) are gaining recognition for their potential to treat a range of conditions, including anxiety-related psychopathology. Despite early promising results, the mechanisms by which psychedelic therapy alleviates anxiety are not well understood. Here, we review neural and cognitive mechanisms underlying anxiety-related psychopathology...

MDMA-Assisted Therapy for Complex-Post-Traumatic Stress Disorder: Toward a neurocognitive account

Philip Gerrans, Hugh Mgovern, Jakob Hohwy et al. 1 citation preprint

Complex post-traumatic stress disorder (C-PTSD) is a newly recognized diagnosis that is distinguished from post-traumatic stress disorder (PTSD) through additional symptom clusters beyond re-experiencing, avoidance, and a persistent sense of threat. In addition to these core PTSD symptoms, C-PTSD is characterized by disturbances in self-organization, including affective dysregulation, negative...

A Systematic and Meta-Analytic Review on Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Mental Illnesses: Effects of Dosage, Psychotherapeutic Support, and Antidepressant Use on Treatment Efficacy

Lena K. L. Oestreich, Hugh McGovern, Zohaib Nadeem et al. preprint

Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...